ASP-9521


Catalog No. Size PriceQuantity
M13315-2 2mg solid $90
M13315-10 10mg solid $270

Description

ASP-9521 is a selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17β-HSD5).

Product information

CAS Number: 1126084-37-4

Molecular Weight: 330.42

Formula: C19H26N2O3

Chemical Name: 1-[1-(5-methoxy-1H-indole-2-carbonyl)piperidin-4-yl]-2-methylpropan-2-ol

Smiles: CC(C)(O)CC1CCN(CC1)C(=O)C1=CC2C=C(C=CC=2N1)OC

InChiKey: OXSCPDKUZWPWFR-UHFFFAOYSA-N

InChi: InChI=1S/C19H26N2O3/c1-19(2,23)12-13-6-8-21(9-7-13)18(22)17-11-14-10-15(24-3)4-5-16(14)20-17/h4-5,10-11,13,20,23H,6-9,12H2,1-3H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 300 mg/mL

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

In vitro, ASP9521 inhibited the conversion of androstenedione into testosterone by recombinant human and cynomolgus monkey AKR1C3 in a concentration-dependent manner, with IC50 values of 11 and 49 nmol/L, respectively. In contrast, ASP9521 did not inhibit the conversion by rat and mouse homologues (AKR1C1 and AKR1C6, respectively) up to a concentration of 10 μmol/L. ASP9521 showed moderately high selectivity (>100-fold) for human AKR1C3 (IC50: 120 nmol/L) over the human isoform AKR1C2 (IC50: >20,000 nmol/L).

In Vivo:

In murine models harbouring CWR22R xenograft tumours, single oral administration of ASP9521 suppressed AD-induced intratumoural testosterone production in a dose-dependent manner. This inhibitory effect was maintained for 24 h after single oral administration of ASP9521. Over this 24 h period, ASP9521 concentration rapidly decreased in plasma from 771.8 ng/mL (mean) to undetectable levels, while its intratumoural concentration reached its maximal level within 15 min after administration of ASP9521 and remained stable for 24 h. In nude mice bearing HEK293 tumours with or without AKR1C3 expression, after single oral administration of ASP9521, plasma concentrations of ASP9521 reached maximum values within 0.25 h (mean: 767.3 ng/mL and 648.2 ng/mL for HEK293 and HEK293-AKR1C3 cells, respectively), but decreased rapidly thereafter. Accumulation of ASP9521 in tumour tissue may depend on AKR1C3 expression. After single oral administration of 1 mg/kg ASP9521 to rats, dogs and monkeys, the drug was rapidly absorbed. The bioavailability values were 35 %, 78 %, and 58 %, respectively. After iv administration of ASP9521 to rats, dogs and monkeys, plasma concentrations of the drug declined with t1/2 values of 0.2, 1.7 and 5.8 h, respectively.

References:

  1. Kikuchi A, et al. In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).Invest New Drugs. 2014 Oct;32(5):860-70.

Products are for research use only. Not for human use.

Payment & Security

American Express Diners Club Discover JCB Mastercard PayPal Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed